DrugBiological
Burosumab clinical trials
Also written KRN23, Crysvita and UX023.
- studies test it
- 25
- open now
- 0
- in phase 3
- 7
- first study started
- 2008
How studies write it
Studies that test it under each name
Studies by the year they started
25 studies that test it; most in 2015 (4)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 5
- Phase 2
- 9
- Phase 3
- 7
- Phase 4
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 18 · Other 7
Kyowa Kirin Co., Ltd. (10) · Kyowa Kirin, Inc. (6) · Kyowa Kirin Pharmaceutical Development Ltd (2) · Laura Tosi (1) · National Institute of Dental and Craniofacial Research (NIDCR) (1) · Yale University (1) · Wuerzburg University Hospital (1) · University of Alabama at Birmingham (1)
Studies
Open first, then newest update. How each study uses burosumab is read from its arms, and is right about nine times in ten.
Testing it · 25
- Burosumab for CSHSCompletedEarly Phase 1Laura TosiNCT03993821Written as Burosumab
- Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous DysplasiaCompletedPhase 2National Institute of Dental and Craniofacial Research (NIDCR)NCT05509595Written as Burosumab
- Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of AgeCompletedPhase 1/2Kyowa Kirin Pharmaceutical Development LtdNCT04188964Written as Burosumab
- Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIOCompletedPhase 4Kyowa Kirin Co., Ltd.NCT05357573Written as KRN23
- Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLHCompletedPhase 4Kyowa Kirin Co., Ltd.NCT04842019Written as KRN23
- Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLHCompletedPhase 4Kyowa Kirin Co., Ltd.NCT04842032Written as KRN23
- Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)CompletedPhase 3Kyowa Kirin, Inc.NCT02537431Written as burosumab
- Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)CompletedPhase 3Kyowa Kirin, Inc.NCT02526160Written as burosumab
- A Repeated Study of KRN23 in Adults With X-Linked HypophosphatemiaCompletedPhase 1/2Kyowa Kirin Co., Ltd.NCT01340482Written as KRN23
- An Extension Study of KRN23 in Adults With X-Linked HypophosphatemiaCompletedPhase 1/2Kyowa Kirin Co., Ltd.NCT01571596Written as KRN23
- A Study of KRN23 in X-linked HypophosphatemiaCompletedPhase 1Kyowa Kirin Co., Ltd.NCT00830674Written as KRN23
- Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)CompletedPhase 2Kyowa Kirin, Inc.NCT02304367Written as Burosumab
- Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)CompletedPhase 2Kyowa Kirin, Inc.NCT02750618Written as Burosumab
- Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)CompletedPhase 2Kyowa Kirin, Inc.NCT02312687Written as KRN23
- Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)CompletedPhase 2Kyowa Kirin, Inc.NCT02163577Written as burosumab
- Examining the Effect of Burosumab on Muscle FunctionCompletedPhase 4Yale UniversityNCT04146935Written as Burosumab Injection [Crysvita]
- Anti-FGF23 (Burosumab) in Adult Patients With XLHCompletedPhase 3Wuerzburg University HospitalNCT04695860Written as Burosumab
- A Trial to Assess the Safety and Efficacy of KRN23 in Epidermal Nevus Syndrome (ENS)CompletedPhase 4University of Alabama at BirminghamNCT04320316Written as Crysvita (burosumab-twza) Treatment
- A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/OsteomalaciaCompletedPhase 3Kyowa Kirin Co., Ltd.NCT03233126Written as KRN23
- A Study of KRN23 in Adult and Pediatric Patients With X-linked Hypophosphatemic Rickets/OsteomalaciaCompletedPhase 3Kyowa Kirin Co., Ltd.NCT04308096Written as KRN23
See all 25 studies that test burosumab →
Given in every arm · 1 — burosumab is usual care beside what is tested
Codes
What other systems call burosumab · ClinicalTrials.gg INT000328
- MeSH (NLM) C000601956burosumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) G9WJT6RD29BUROSUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2043855Confirmed FDA, Wikidata
- Wikidata Q28209068BurosumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C119744BurosumabOne source FDA
- DrugBank DB14012One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000601956 | burosumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | G9WJT6RD29 | BUROSUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2043855 | — | Confirmed FDA, Wikidata |
| Wikidata | Q28209068 | Burosumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C119744 | Burosumab | One source FDA |
| DrugBank | DB14012 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.